Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 2/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | WNT1 | P04628 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12699863 | 0.79 | CYP1A2 (0.36) | SCN1ASCN2ASCN3ACYP1A2TDP1 | |
| SCHEMBL22214938 | 0.79 | CYP1A2 (0.41) | SCN1ASCN2ASCN3ACYP1A2TDP1 | |
| Hydrochloric Acid SCHEMBL22189246 | 0.77 | OPRM1 (0.36) | SCN1ASCN2ASCN3ACYP1A2TDP1 | |
| SCHEMBL14888691 | 0.77 | CYP1A2 (0.34) | SCN1ASCN2ASCN3ACYP1A2TDP1 | |
| SCHEMBL231971 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL14311912 | 0.76 | OPRM1 (0.33) | SCN1ASCN2ASCN3ACYP1A2TDP1 | |
| SCHEMBL12409989 | 0.75 | — | — | |
| SCHEMBL17727844 | 0.74 | SCN1A (0.41) | SCN1ASCN2ASCN3ACYP1A2TDP1 | |
| SCHEMBL24127261 | 0.74 | CYP1A2 (0.32) | SCN1ASCN2ASCN3ACYP1A2TDP1 | |
| SCHEMBL25672291 | 0.74 | OPRM1 (0.36) | CYP1A2TDP1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220089613-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220089613-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2022-03-24 | — | — | US | disclosed |
| US-11220518-B2 | Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11220518-B2 | Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-10316045-B2 | Substituted pyrrolo[3,4-c]pyrazoles as pkc kinase inhibitors | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316045-B2 | Substituted pyrrolo[3,4-c]pyrazoles as pkc kinase inhibitors | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170217991-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2017-08-03 | — | — | US | disclosed |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-05-27 | — | — | US | disclosed |
| CN-101675052-A | 3-amido-pyrrolo [3, 4-C ] pyrazole-5 (1H,4H,6H) carbaldehyde derivatives as protease C inhibitors | PFIZER | 2010-03-17 | — | — | CN | disclosed |
| CN-101646673-A | 3-amino-pyrrolo [3, 4-C ] pyrazole-5 (1H,4H,6H) carbaldehyde derivatives as PKC inhibitors | PFIZER US | 2010-02-10 | — | — | CN | disclosed |
| EP-2118112-A1 | 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS | Pfizer Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008125945-A2 | 3-AMIDO-PYRROLO [3, 4-C] PYRAZOLE-5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C | PFIZER INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125945-A2 | 3-AMIDO-PYRROLO [3, 4-C] PYRAZOLE-5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C | PFIZER INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008096260-A1 | 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS | PFIZER INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096260-A1 | 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS | PFIZER INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217991-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | INSR, IAPP, GPR119 | SCN1A 3913/4885SCN2A 4371/4885SCN3A 2737/4885 |
| US-10316045-B2 | Substituted pyrrolo[3,4-c]pyrazoles as pkc kinase inhibitors | PRKCB, PRKCA, PRKCE | SCN1A 4360/4885SCN2A 4590/4885SCN3A 3461/4885 |
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PRKCB, PRKCA, PRKCQ | SCN1A 2863/4885SCN2A 2790/4885SCN3A 2440/4885 |
| US-11220518-B2 | Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors | JAK3, PRKCB, PRKCA | SCN1A 3150/4885SCN2A 3727/4885SCN3A 2321/4885 |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | DPP3, IAPP, GPR119 | SCN1A 4070/4885SCN2A 4502/4885SCN3A 2914/4885 |
| US-20220089613-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | INSR, IAPP, GPR119 | SCN1A 3913/4885SCN2A 4371/4885SCN3A 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.